Ligand Pharmaceuticals (LGND) Assets (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Assets of $1.5 billion for Q1 2026, down 1.83% sequentially from $1.6 billion in Q4 2025, and up 69.21% YoY from $905.4 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Assets (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Assets for 17 years, with the latest figure at $1.5 billion in Q1 2026.
- Quarterly Assets rose 69.21% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 69.21% YoY) and the FY2025 annual result came in at $1.6 billion, up 65.71% from the prior year.
- Assets fell to $1.5 billion in Q1 2026 per LGND's latest filing, from $1.6 billion in the prior quarter.
- Over five years, Assets peaked at $1.6 billion in Q4 2025 and troughed at $758.1 million in Q2 2023.
- A 5-year average of $1.0 billion and a median of $941.8 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2026: Assets slumped 41.22% in 2022, then jumped 69.21% in 2026.
- Over 5 years, Assets stood at $762.7 million in 2022, then climbed by 3.22% to $787.2 million in 2023, then grew by 19.63% to $941.8 million in 2024, then jumped by 65.71% to $1.6 billion in 2025, then declined by 1.83% to $1.5 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $1.5 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 2.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.19 Bn |
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.56 Bn |
| Sep 30, 2025 | 1.48 Bn |
| Jun 30, 2025 | 948.60 Mn |
| Mar 31, 2025 | 905.44 Mn |
| Dec 31, 2024 | 941.77 Mn |
| Sep 30, 2024 | 954.87 Mn |
| Jun 30, 2024 | 866.41 Mn |
| Mar 31, 2024 | 913.87 Mn |
| Dec 31, 2023 | 787.22 Mn |
| Sep 30, 2023 | 769.23 Mn |
| Jun 30, 2023 | 758.11 Mn |
| Mar 31, 2023 | 811.08 Mn |
| Dec 31, 2022 | 762.67 Mn |
| Sep 30, 2022 | 1.05 Bn |
| Jun 30, 2022 | 1.08 Bn |
| Mar 31, 2022 | 1.11 Bn |
| Dec 31, 2021 | 1.30 Bn |
| Sep 30, 2021 | 1.27 Bn |